Candela Introduces Next Generation Intense Pulsed Light Technology
"Candela is thrilled to add this next generation technology to our well established, state of the art laser portfolio," said Gerard E. Puorro, Candela's President and Chief Executive Officer. "With the addition of the Ellipse I2PL system, we have expanded our product offerings to provide our customers with a broader base of technologies from which to choose."
Puorro continued, "Candela is recognized as a leader in the aesthetic device industry. We recognize that no single technology can meet each customer's individual needs. Through our new Pathways Program, customers now have the flexibility to choose from multiple technology platforms for the optimum laser or light based technology that suits their needs. The combination of Candela lasers and the Ellipse I2PL system creates a complete package."
Dr. Christine Dierickx, Medical Director of the Laser and Skin Clinic in Boom, Belgium, commented, "I have been using the Ellipse I2PL system from DDD for the past 3 years. I find the system very easy to use and the clinical performance very consistent from patient to patient. The unique I2PL technology removes undesirable wavelengths which improves clinical outcomes in patients while minimizing side effects."
Ellipse is currently sold in more than 40 countries worldwide. DDD was formed in 1997 and is one of the largest manufacturers of intense pulsed light systems in the world. They are a fast growing, innovative and quality focused company providing high tech products and solutions for light based treatment of skin disease and cosmetic disorders.
"The collaboration between DDD and Candela Corporation is extremely natural for the companies," said Gert Toftkjaer, DDD's Managing Director. "We are both technology leaders in the dermatology field and share the same goals of quality and customer satisfaction. Candela has the largest and most comprehensive distribution networks in America and will continue to grow with the addition of the Ellipse I2PL system."
Candela's new Pathways Program is all about choices for the customer. Through a platform of upgradeable technologies, customers can choose from a variety of technologies for the specific clinical applications they are interested in treating. These technologies include diode technology, solid state laser, pulsed dye laser and intense pulsed light systems. No other company offers such a wide array of technology choices and clinical applications.
The Ellipse I2PL system is pending FDA clearance in the United States. The Ellipse I2PL system will be available for purchase after receipt of FDA clearance.